Key facts
- This page summarizes Ryan Blust's Form 3 filing for Trulieve Cannabis Corp. (TCNNF).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 11 Mar 2025, 16:11.
Ryan Blust - 06 Mar 2025 Form 3 Insider Report for Trulieve Cannabis Corp. (TCNNF)
- Reporting relationship
- Interim CFO
- Issuer ticker
- TCNNF
- Reported as of
- 06 Mar 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 11 Mar 2025, 16:11:46 UTC
- Prior SEC filing
- 16 Jan 2024
- Next SEC filing
- 28 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ryan Blust
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ryan Blust filed Form 3 for Trulieve Cannabis Corp. (TCNNF) on 11 Mar 2025.
Change
- Previous filing in this sequence was filed on 16 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRUL
holding
Subordinate Voting Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 54,298
- Date
- 06 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRUL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Mar 2025
- Ownership
- Direct
- Underlying class
- Subordinate Voting Shares
- Underlying amount
- 7,497
- Exercise price
- $33.42
- Footnotes
- F2
TRUL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Mar 2025
- Ownership
- Direct
- Underlying class
- Subordinate Voting Shares
- Underlying amount
- 19,458
- Exercise price
- $26.88
- Footnotes
- F3
TRUL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Mar 2025
- Ownership
- Direct
- Underlying class
- Subordinate Voting Shares
- Underlying amount
- 24,860
- Exercise price
- $21.48
- Footnotes
- F4
TRUL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Mar 2025
- Ownership
- Direct
- Underlying class
- Subordinate Voting Shares
- Underlying amount
- 56,442
- Exercise price
- $3.99
- Footnotes
- F5
TRUL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Mar 2025
- Ownership
- Direct
- Underlying class
- Subordinate Voting Shares
- Underlying amount
- 33,114
- Exercise price
- $10.00
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The amount of securities beneficially owned in column 2 includes two grants of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Trulieve Cannabis Corp. subordinate voting share. The reporting person was granted: (i) 25,364 RSUs on July 25, 2023, subject to 2-year vesting; the RSUs vested 50% on December 1, 2024 and will vest 50% on December 1, 2025; and (ii) 18,288 RSUs on March 8, 2024, subject to 2-year vesting; the RSUs will vest 50% on December 1, 2025 and 50% on December 1, 2026.
Footnote F2
The options were granted on January 4, 2021. As of December 31, 2023, all of the options were fully vested and exercisable.
Footnote F3
The options were granted on September 29, 2021. As of December 1, 2023, all of the options were fully vested and exercisable.
Footnote F4
The options were granted on February 24, 2022. As of December 1, 2024, all of the options were fully vested and exercisable.
Footnote F5
The options were granted on July 25, 2023, and vest 33% per year in equal installments, starting on December 1 of the grant year. One third of the options vested and became exercisable on December 1, 2023; one third of the options vested and became exercisable on December 1, 2024; and one third of the options will vest and become exercisable on December 1, 2025.
Footnote F6
The options were granted on March 8, 2024, and vest 33% per year in equal installments, starting on December 1 of the grant year. One third of the options vested and became exercisable on December 1, 2024; one third of the options will vest and become exercisable on December 1, 2025; and one third of the options will vest and become exercisable on December 1, 2026.